Patents Assigned to Actinium Pharmaceuticals, Inc.
-
Patent number: 11975081Abstract: Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.Type: GrantFiled: October 5, 2023Date of Patent: May 7, 2024Assignee: Actinium Pharmaceuticals, Inc.Inventors: Le-Cun Xu, Denis Beckford Vera
-
Publication number: 20240131025Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: ApplicationFiled: November 1, 2023Publication date: April 25, 2024Applicant: Actinium Pharmaceuticals, Inc.Inventor: Dragan Cicic
-
Patent number: 11964948Abstract: Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.Type: GrantFiled: October 8, 2023Date of Patent: April 23, 2024Assignee: Actinium Pharmaceuticals, Inc.Inventors: Le-Cun Xu, Denis Beckford Vera
-
Publication number: 20240082438Abstract: Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.Type: ApplicationFiled: October 5, 2023Publication date: March 14, 2024Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventors: Le-Cun XU, Denis BECKFORD-VERA
-
Patent number: 11912780Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.Type: GrantFiled: October 25, 2018Date of Patent: February 27, 2024Assignee: ACTINIUM PHARMACEUTICALS, INC.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20240051928Abstract: Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.Type: ApplicationFiled: October 8, 2023Publication date: February 15, 2024Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventors: Le-Cun XU, Denis BECKFORD-VERA
-
Patent number: 11844799Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: GrantFiled: May 16, 2022Date of Patent: December 19, 2023Assignee: Actinium Pharmaceuticals, Inc.Inventor: Dragan Cicic
-
Publication number: 20230132400Abstract: Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 are disclosed. One or both of the anti-CD33 and anti-CD38 antibodies may be labeled with a radioisotope. The antibodies may be administered sequentially or simultaneously. Moreover, each antibody may be administered according to a specific dosing schedule, wherein the administration may be sequential (i.e., one antibody dosing schedule is completed before the next antibody dosing schedule is started) or simultaneous.Type: ApplicationFiled: November 13, 2018Publication date: April 27, 2023Applicant: Actinium Pharmaceuticals, Inc.Inventors: Sandesh SETH, Keisha THOMAS
-
Publication number: 20220273648Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: ApplicationFiled: May 16, 2022Publication date: September 1, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventor: Dragan Cicic
-
Patent number: 11406724Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: GrantFiled: March 11, 2019Date of Patent: August 9, 2022Assignee: ACTINIUM PHARMACEUTICALS, INC.Inventors: Kaushik J. Dave, Shubh D. Sharma
-
Publication number: 20220211885Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells that includes administering to the subject an effective amount of a radiolabeled antibody against CD34, CD117, or CD135, where preferred radiolabels include 131I and 225Ac. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy, where the method includes (i) administering to the subject an amount of the radiolabeled antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.Type: ApplicationFiled: April 24, 2020Publication date: July 7, 2022Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventor: Dale L. Ludwig
-
Publication number: 20220202967Abstract: Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19, CD20, CD33, CD38, CD45RA, CD52, or a combination thereof. The effective amount of the radiolabeled antibody depletes at least 50% of the targeted immune cells, and less than 20% of the subject's stem cells. When used alone, these methods may target lymphomas, leukemias, and myelomas, and/or may additionally allow repopulation of non-autoreactive immune cells in patients with an autoimmune disease. When these methods precede certain cell-based therapies, such as adoptive cell therapy and/or hematopoietic stem cell therapy, the methods are able to enhance the outcome of the cell-based therapies while minimizing adverse effects.Type: ApplicationFiled: April 24, 2020Publication date: June 30, 2022Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventors: Dale Ludwig, Eileen Geoghegan
-
Patent number: 11364235Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: GrantFiled: April 26, 2018Date of Patent: June 21, 2022Assignee: Actinium Pharmaceuticals, Inc.Inventor: Dragan Cicic
-
Publication number: 20220125962Abstract: This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) each actinium atom is either 227Ac or 225Ac, and (c) the molar ratio of 227Ac to 225Ac in the composition is at least 1:1, This invention also provides related synthetic compositions and methods, as well as methods for treating hematologic malignancies.Type: ApplicationFiled: November 27, 2019Publication date: April 28, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventors: Dale Ludwig, Steve O'Loughlin, Vimal Patel, Nitya Ray, Sandesh Seth
-
Patent number: 11292835Abstract: This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225Ac-HuM195.Type: GrantFiled: May 25, 2017Date of Patent: April 5, 2022Assignee: Actinium Pharmaceuticals, Inc.Inventor: Dragan Cicic
-
Publication number: 20220072167Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the PARP inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets the cancer cell, wherein the amounts of PARP inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: ApplicationFiled: January 2, 2020Publication date: March 10, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventors: Dale Ludwig, Sandesh Seth
-
Patent number: 11241512Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: GrantFiled: June 28, 2019Date of Patent: February 8, 2022Assignee: Actinium Pharmaceuticals, Inc.Inventors: Kaushik Dave, Shubh Sharma
-
Publication number: 20220008570Abstract: Methods for treating a proliferative disease or disorder by administering a radioimmunotherapy to generate an immune response in combination with immune checkpoint therapy to further enhance the immune response.Type: ApplicationFiled: December 23, 2019Publication date: January 13, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventor: Dale Ludwig
-
Publication number: 20210198359Abstract: This invention provides a method for depleting a subject's immune cells, where the method includes administering to the subject an effective amount of a radiolabeled anti-CD45 antibody. This invention also provides a method for treating a subject afflicted with cancer, where the method includes (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's lymphocytes, and (ii) after a suitable time period, performing adoptive cell therapy on the subject to treat the subject's cancer. Finally, this invention provides an article of manufacture including (a) a radiolabeled anti-CD45 antibody, and (b) a label instructing the user to administer to a subject an amount of the antibody effective to deplete the subject's immune cells.Type: ApplicationFiled: October 25, 2018Publication date: July 1, 2021Applicant: Actinium Pharmaceuticals, Inc.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20210179710Abstract: Methods for treating a proliferative disease by administering a synergistic combination of an antibody against an epitope of CD33 (anti-CD33) and a combination of two or more individual chemotherapeutic agents is disclosed. The combination of chemotherapeutic agents may include cladribine, cytarabine, mitoxantrone, and filgrastim (CLAG-M), and the anti-CD33 may be a humanized monoclonal antibody against CD33 such as HuM195 conjugated with a radionuclide such as 131I or 225Ac. The proliferative disease or disorder may be a hematological disease such as multiple myeloma, acute myeloid leukemia, and/or myelodysplastic syndrome. The method may be particularly useful for treatment of relapsed or refractory acute myeloid leukemia.Type: ApplicationFiled: January 8, 2019Publication date: June 17, 2021Applicant: Actinium Pharmaceuticals, Inc.Inventor: Mark Berger